284 related articles for article (PubMed ID: 34996497)
21. Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours.
Bremmer F; Schallenberg S; Jarry H; Küffer S; Kaulfuss S; Burfeind P; Strauß A; Thelen P; Radzun HJ; Ströbel P; Honecker F; Behnes CL
Oncotarget; 2015 Oct; 6(32):33426-37. PubMed ID: 26451610
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic Priming and Development of New Combination Therapy Approaches.
Meneceur S; Grunewald CM; Niegisch G; Hoffmann MJ
Methods Mol Biol; 2023; 2684():259-281. PubMed ID: 37410240
[TBL] [Abstract][Full Text] [Related]
23. A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer.
Albany C; Fazal Z; Singh R; Bikorimana E; Adra N; Hanna NH; Einhorn LH; Perkins SM; Sandusky GE; Christensen BC; Keer H; Fang F; Nephew KP; Spinella MJ
Cancer Med; 2021 Jan; 10(1):156-163. PubMed ID: 33135391
[TBL] [Abstract][Full Text] [Related]
24. Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells.
Gerwing M; Jacobsen C; Dyshlovoy S; Hauschild J; Rohlfing T; Oing C; Venz S; Oldenburg J; Oechsle K; Bokemeyer C; von Amsberg G; Honecker F
J Cancer Res Clin Oncol; 2016 Sep; 142(9):1979-94. PubMed ID: 27424191
[TBL] [Abstract][Full Text] [Related]
25. Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples.
Lobo J; Constâncio V; Leite-Silva P; Guimarães R; Cantante M; Braga I; Maurício J; Looijenga LHJ; Henrique R; Jerónimo C
Clin Epigenetics; 2021 Apr; 13(1):70. PubMed ID: 33823933
[TBL] [Abstract][Full Text] [Related]
26. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract][Full Text] [Related]
27. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
[TBL] [Abstract][Full Text] [Related]
28. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
[TBL] [Abstract][Full Text] [Related]
29. Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies.
Burmeister A; Stephan A; Alves Avelar LA; Müller MR; Seiwert A; Höfmann S; Fischer F; Torres-Gomez H; Hoffmann MJ; Niegisch G; Bremmer F; Petzsch P; Köhrer K; Albers P; Kurz T; Skowron MA; Nettersheim D
Mol Cancer Ther; 2022 Nov; 21(11):1674-1688. PubMed ID: 35999659
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract][Full Text] [Related]
31. The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?
Ottaviano M; Giunta EF; Rescigno P; Pereira Mestre R; Marandino L; Tortora M; Riccio V; Parola S; Casula M; Paliogiannis P; Cossu A; Vogl UM; Bosso D; Rosanova M; Mazzola B; Daniele B; Palmieri G; Palmieri G
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281219
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic Treatment Options in Urothelial Carcinoma.
Pinkerneil M; Hoffmann MJ; Niegisch G
Methods Mol Biol; 2018; 1655():289-317. PubMed ID: 28889393
[TBL] [Abstract][Full Text] [Related]
33. The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas.
Skowron MA; Becker TK; Kurz L; Jostes S; Bremmer F; Fronhoffs F; Funke K; Wakileh GA; Müller MR; Burmeister A; Lenz T; Stefanski A; Stühler K; Petzsch P; Köhrer K; Altevogt P; Albers P; Kristiansen G; Schorle H; Nettersheim D
Mol Oncol; 2022 Feb; 16(4):982-1008. PubMed ID: 34293822
[TBL] [Abstract][Full Text] [Related]
34. Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin.
Korkola JE; Houldsworth J; Bosl GJ; Chaganti RS
BJU Int; 2009 Nov; 104(9 Pt B):1334-8. PubMed ID: 19840009
[TBL] [Abstract][Full Text] [Related]
35. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers.
Noel EE; Yeste-Velasco M; Mao X; Perry J; Kudahetti SC; Li NF; Sharp S; Chaplin T; Xue L; McIntyre A; Shan L; Powles T; Oliver RT; Young BD; Shipley J; Berney DM; Joel SP; Lu YJ
Am J Pathol; 2010 Jun; 176(6):2607-15. PubMed ID: 20395447
[TBL] [Abstract][Full Text] [Related]
36. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.
Honecker F; Wermann H; Mayer F; Gillis AJ; Stoop H; van Gurp RJ; Oechsle K; Steyerberg E; Hartmann JT; Dinjens WN; Oosterhuis JW; Bokemeyer C; Looijenga LH
J Clin Oncol; 2009 May; 27(13):2129-36. PubMed ID: 19289622
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin related cardiotoxicity - acute and chronic cardiovascular morbidity in a testicular cancer survivor.
Morrow AJ; Cameron AC; Payne AR; White J; Lang NN
Scott Med J; 2020 Feb; 65(1):24-27. PubMed ID: 31886736
[No Abstract] [Full Text] [Related]
38. Investigational targeted therapies for the treatment of testicular germ cell tumors.
Oing C; Kollmannsberger C; Oechsle K; Bokemeyer C
Expert Opin Investig Drugs; 2016 Sep; 25(9):1033-43. PubMed ID: 27286362
[TBL] [Abstract][Full Text] [Related]
39. Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.
Bagrodia A; Lee BH; Lee W; Cha EK; Sfakianos JP; Iyer G; Pietzak EJ; Gao SP; Zabor EC; Ostrovnaya I; Kaffenberger SD; Syed A; Arcila ME; Chaganti RS; Kundra R; Eng J; Hreiki J; Vacic V; Arora K; Oschwald DM; Berger MF; Bajorin DF; Bains MS; Schultz N; Reuter VE; Sheinfeld J; Bosl GJ; Al-Ahmadie HA; Solit DB; Feldman DR
J Clin Oncol; 2016 Nov; 34(33):4000-4007. PubMed ID: 27646943
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of everolimus in refractory testicular germ cell tumors.
Mego M; Svetlovska D; Miskovska V; Obertova J; Palacka P; Rajec J; Sycova-Mila Z; Chovanec M; Rejlekova K; Zuzák P; Ondrus D; Spanik S; Reckova M; Mardiak J
Urol Oncol; 2016 Mar; 34(3):122.e17-22. PubMed ID: 26612480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]